Literature DB >> 31802325

Advances in the Diagnosis and Management of Tubercular Meningitis in Children.

Himani Bhasin1, Medha Goyal2, Suvasini Sharma3.   

Abstract

Tubercular meningitis (TBM) continues to be a common cause of neuromorbidity in children. There is no single diagnostic method that can rapidly detect Mycobacterium tuberculosis (M.tb) in TBM patients with high sensitivity and specificity. Newer diagnostic modalities like Xpert/RIF assay and Loop mediated isothermal amplification assay (LAMP) have gained an essential stand in molecular diagnostics due to their high specificity, modest sensitivity in cerebrospinal fluid (CSF) and quick availability of results. Intensified drug regimens using high dose rifampicin, fluoroquinolone and aspirin appear to be useful adjunct therapy but more pediatric clinical trials on large scale are needed to determine their appropriate place in pediatric TBM. The emergence of multi and extreme drug resistant M.tb strains further challenges the standard therapy. In this review authors summarize challenges of the currently used diagnostic methods and treatment for TBM and discuss the recent advances.

Entities:  

Keywords:  Chronic meningitis; GeneXpert; MDR; PCR; Pyrosequencing; XDR

Mesh:

Substances:

Year:  2019        PMID: 31802325     DOI: 10.1007/s12098-019-03089-x

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  37 in total

1.  Chest computerized tomography scan findings in 74 children with tuberculous meningitis in southeastern Turkey.

Authors:  Ahmet Yaramiş; Yaşar Bükte; Selahattin Katar; M Nuri Ozbek
Journal:  Turk J Pediatr       Date:  2007 Oct-Dec       Impact factor: 0.552

2.  Diagnostic usefulness of Xpert MTB/RIF assay for detection of tuberculous meningitis using cerebrospinal fluid.

Authors:  Syed Beenish Rufai; Amit Singh; Jitendra Singh; Parveen Kumar; Manimuthu Mani Sankar; Sarman Singh
Journal:  J Infect       Date:  2017-05-10       Impact factor: 6.072

3.  Tuberculous meningitis: is a 6-month treatment regimen sufficient?

Authors:  J H van Loenhout-Rooyackers; A Keyser; R J Laheij; A L Verbeek; J W van der Meer
Journal:  Int J Tuberc Lung Dis       Date:  2001-11       Impact factor: 2.373

Review 4.  Cerebrospinal fluid concentrations of antituberculosis agents in adults and children.

Authors:  P R Donald
Journal:  Tuberculosis (Edinb)       Date:  2010-08-14       Impact factor: 3.131

Review 5.  Tuberculous meningitis.

Authors:  R K Garg
Journal:  Acta Neurol Scand       Date:  2010-01-06       Impact factor: 3.209

6.  Surgical outcome of tuberculous meningitis hydrocephalus treated by endoscopic third ventriculostomy: prognostic factors and postoperative neuroimaging for functional assessment of ventriculostomy.

Authors:  Ashish Chugh; Mazhar Husain; Rakesh K Gupta; Bal K Ojha; Anil Chandra; Manu Rastogi
Journal:  J Neurosurg Pediatr       Date:  2009-05       Impact factor: 2.375

7.  Definitive neuroradiological diagnostic features of tuberculous meningitis in children.

Authors:  Savvas Andronikou; Bruce Smith; Mark Hatherhill; Hassan Douis; Jo Wilmshurst
Journal:  Pediatr Radiol       Date:  2004-09-17

8.  Short intensified treatment in children with drug-susceptible tuberculous meningitis.

Authors:  Ronald van Toorn; H Simon Schaaf; Jacoba A Laubscher; Sabine L van Elsland; Peter R Donald; Johan F Schoeman
Journal:  Pediatr Infect Dis J       Date:  2014-03       Impact factor: 2.129

9.  Evaluation of cerebral arterial and venous system in tuberculous meningitis.

Authors:  Jayantee Kalita; Rajesh K Singh; Usha K Misra; Sunil Kumar
Journal:  J Neuroradiol       Date:  2017-09-29       Impact factor: 3.447

10.  Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.

Authors:  Dorothee Heemskerk; Jeremy Day; Tran Thi Hong Chau; Nguyen Huy Dung; Nguyen Thi Bich Yen; Nguyen Duc Bang; Laura Merson; Piero Olliaro; Thomas Pouplin; Maxine Caws; Marcel Wolbers; Jeremy Farrar
Journal:  Trials       Date:  2011-02-02       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.